Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.
Short position
Clinuvel Pharmaceuticals (ASX:CUV) has 9.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,572,694 shares. Over the past 30 days that figure has risen 0.96 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 10.04% in August 2020. CUV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Clinuvel Pharmaceuticals (CUV) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $94.0Mvs $95.0M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $33.9Mvs $36.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.67vs $0.72 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- −1.0%FY
- EPS YoY
- −7.0%FY
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 83.2%
- Operating margin
- 42.1%
- Net margin
- 36.1%
- FCF margin
- 37.6%
- ROE
- 13.2%
- ROA
- 12.0%
- FCF conversion
- 1.04×
- Net cash (excl. leases)
- $252.1M
- Net debt / EBITDA
- −6.2×
- Current ratio
- 14.8×
- Interest cover
- n/a
- Cash dividends paid / net profit
- 7.4%
- Market cap
- $400.4M
- P/E
- 11.9×
- P/B
- 1.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $94.0M | $95.0M | $88.2M | $78.3M |
| Gross profit | $78.2M | $79.1M | $78.1M | $69.5M |
| Operating income | $39.5M | $45.7M | $48.0M | $44.1M |
| EBITDA | $40.5M | $57.2M | $56.3M | $49.6M |
| EBIT | $39.5M | $56.0M | $55.1M | $48.8M |
| Interest expense | n/a | $4.5M | $4.5M | $3.2M |
| Pretax income | $47.7M | $51.6M | $50.7M | $45.6M |
| Tax | $13.7M | $15.4M | $15.0M | $15.0M |
| NPAT | $33.9M | $36.2M | $35.6M | $30.6M |
| Net interest income | $10.4M | $5.0M | $2.9M | $713.1K |
| EPS basic | $0.68 | $0.72 | $0.71 | $0.62 |
| EPS diluted | $0.67 | $0.72 | $0.70 | $0.59 |
| Shares | 50.4M | 50.1M | 50.1M | 49.4M |
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual Report to Shareholders 2026Annual Results27 Aug 2026via asx_announcements
- CLINUVEL Annual Results - Investor WebinarFinancial Report20 Aug 2026via asx_announcements
- CLINUVEL Investor Webinar Half Year Results December 2025Half Year Results5 Mar 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results26 Feb 2026via asx_announcements
- Half Year Results PresentationHalf Year Results26 Feb 2026via asx_announcements
- Financial ReportFinancial Report31 Dec 2025via crawler
- CLINUVEL Annual Results - Investor WebinarFinancial Report29 Aug 2025via asx_announcements
- Appendix 4E and Annual Report to Shareholders 2025Annual Results28 Aug 2025via asx_announcements
- CLINUVEL Annual Results - Investor WebinarFinancial Report21 Aug 2025via asx_announcements
- Half Year Results AnnouncementHalf Year Results27 Feb 2025via asx_announcements
Showing 10 of 26 reports